Wednesday, 22 January 2014

Xigduo™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes

AstraZeneca and Bristol-Myers Squibb today announced that Xigduo™ (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union (AstraZeneca)


Body mass index thresholds for intervening to prevent ill health among black, Asian and other minority ethnic groups

The prevalence of chronic conditions such as type 2 diabetes, coronary heart disease and stroke is up to 6 times higher (and they occur from a younger age) among black, Asian and other minority ethnic groups. In addition, these groups progress from being at-risk to being diagnosed with these conditions at twice the rate of white populations. (NICE)


Characteristics of Glucose Metabolism in Nordic and South Asian Subjects with Type 2 Diabetes

Subjects of South Asian ethnicity with type 2 diabetes, despite being younger and leaner, had higher basal endogenous glucose production, indicating higher hepatic insulin resistance, and a trend towards higher use of carbohydrates as fasting energy substrate compared to Nordic subjects. These findings may contribute to the understanding of the observed differences in prevalence of type 2 diabetes between the ethnic groups. (PLoS ONE)


The effect of withdrawal of rosiglitazone on treatment pathways, diabetes control and patient outcomes: A retrospective cohort study

Withdrawal of rosiglitazone was associated with worsening glucose control and subsequent intensification of treatment regimen (Diabetes and Its Complications)

No comments:

Post a Comment